A LinkedIn post from HOPPR profiles Innovation Research Scientist Kalina Slavkova, PhD, emphasizing her role in advancing AI-driven medical imaging within the company’s Innovation and Clinical Research Team. The post highlights her academic background in physics, oncology-focused MRI research, and postdoctoral work at the University of Pennsylvania and Columbia University on MRI-based biomarkers and deep learning methods.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, Slavkova collaborates with clinicians, engineers, and research partners to translate technical advances into practical clinical impact and supports HOPPR’s academic collaborators. The post also notes her leading role in developing HOPPR’s recent whitepaper on fine-tuning foundation models for medical imaging, suggesting a strategic focus on cutting-edge AI research that could strengthen the company’s technology differentiation and appeal to enterprise and institutional partners.
The emphasis on foundation models and contrast synthesis, tumor segmentation, and imaging biomarkers points to capabilities that may be relevant for oncology workflows and risk stratification, areas of growing commercial interest in medical imaging AI. For investors, the profile suggests HOPPR is investing in high-caliber research talent and academic collaboration, which could enhance its long-term innovation pipeline, support evidence-based product development, and potentially improve its competitive position in the AI-enabled imaging market.